Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

BACKGROUND: The efficacy of cardiac iron chelation in transfusion-dependent patients has been demonstrated in one-year prospective trials. Since normalization of cardiac T2* takes several years, the efficacy and safety of deferasirox was assessed for two years in patients with β-thalassemia major in...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Pennell, Dudley J., Porter, John B., Cappellini, Maria Domenica, Chan, Lee Lee, El-Beshlawy, Amal, Aydinok, Yesim, Ibrahim, Hishamshah, Li, Chi-Kong, Viprakasit, Vip, Elalfy, Mohsen Saleh, Kattamis, Antonis, Smith, Gillian, Habr, Dany, Domokos, Gabor, Roubert, Bernard, Taher, Ali
פורמט: Artigo
שפה:Inglês
יצא לאור: Ferrata Storti Foundation 2011
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3012764/
https://ncbi.nlm.nih.gov/pubmed/21071497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.031468
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים